1
Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain
Condition(s):Neuropathic PainLast Updated:August 25, 2017Terminated
Loxapine as an Intervention: 35 Clinical Trials
Hide Studies Not Open or Pending
2
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Condition(s):Psychomotor Agitation; Schizophrenia; Bipolar DisorderLast Updated:November 4, 2019Not yet recruiting
3
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
Condition(s):Agitation,PsychomotorLast Updated:July 30, 2019Recruiting
4
Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting
Condition(s):AgitationLast Updated:October 3, 2019Recruiting
5
Staccato Loxapine in Agitated Patients With Schizophrenia
Condition(s):Patients With Schizophrenia and Acute AgitationLast Updated:June 28, 2017Completed
6
Staccato Loxapine Pulmonary Safety in Patients With Asthma
Condition(s):AsthmaLast Updated:March 13, 2017Completed
7
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
Condition(s):Agitation,Psychomotor; Haloperidol Causing Adverse Effects in Therapeutic Use; Lorazepam Causing Adverse Effects in Therapeutic Use; Loxapine Causing Adverse Effects in Therapeutic UseLast Updated:May 11, 2018Terminated
8
Staccato Loxapine PK in Smokers and Nonsmokers
Condition(s):Smoking, CigaretteLast Updated:March 13, 2017Completed
9
Staccato Loxapine in Migraine (in Clinic)
Condition(s):MigraineLast Updated:June 13, 2017Completed
10
Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
Condition(s):BiPolarLast Updated:February 26, 2016Completed
11
Staccato Loxapine Pulmonary Safety in Patients With COPD
Condition(s):Chronic Obstructive Pulmonary DiseaseLast Updated:March 13, 2017Completed
12
Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning
Condition(s):RestlessnessLast Updated:July 17, 2014Completed
13
Staccato Loxapine in Agitation (Proof of Concept)
Condition(s):SchizophreniaLast Updated:May 30, 2017Completed
14
Staccato Loxapine in Agitated Patients With Bipolar Disorder
Condition(s):Bipolar I DisorderLast Updated:June 28, 2017Completed
15
Staccato Loxapine Pulmonary Safety in Healthy Volunteers
Condition(s):HealthyLast Updated:November 18, 2018Completed
16
Staccato Loxapine in Migraine (Out Patient)
Condition(s):Migraine HeadacheLast Updated:March 13, 2017Completed
17
Staccato Loxapine Multidose PK
Condition(s):Volunteers on Chronic, Stable Antipsychotic RegimensLast Updated:March 13, 2017Completed
18
Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients
Condition(s):Acute Agitated PatientsLast Updated:March 10, 2015Terminated
19
Staccato Loxapine Single Dose PK
Condition(s):SchizophreniaLast Updated:November 17, 2018Completed
20
Loxapine and Weaning From Ventilator
Condition(s):Respiratory Insufficiency; Psychomotor AgitationLast Updated:July 20, 2007Completed
21
Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg
Condition(s):HealthyLast Updated:March 31, 2008Completed
22
Staccato Loxapine Thorough QT/QTc Study
Condition(s):Thorough QT/QTc StudyLast Updated:October 29, 2019Completed
23
ADASUVE 2-dose Thorough QT/QTc Study
Condition(s):Healthy VolunteersLast Updated:September 26, 2017Completed
24
ADASUVE-Lorazepam Drug-Drug Interaction
Condition(s):Healthy VolunteersLast Updated:November 15, 2017Completed
25
Naturalistic Adasuve Clinical Trial Study
Condition(s):AgitationLast Updated:August 23, 2016Unknown status
26
Outcomes of Antipsychotic Medication Used in the Emergency Department
Condition(s):Agitation,PsychomotorLast Updated:July 27, 2016Completed
27
Staccato Prochlorperazine Thorough QT/QTc
Condition(s):CardiotoxicityLast Updated:November 19, 2018Completed
28
Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms
Condition(s):Schizophrenia; Schizoaffective DisorderLast Updated:August 8, 2018Active, not recruiting
29
Antipsychotic Induced Structural and Functional Brain Changes
Condition(s):SchizophreniaLast Updated:December 21, 2017Unknown status
30
Antipsychotics and Risk of Hyperglycemic Emergencies
Condition(s):Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Diabetes Mellitus, Type 2Last Updated:October 20, 2015Completed
31
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
Condition(s):SchizophreniaLast Updated:January 21, 2019Completed
32
Haloperidol vs Olanzapine for the Management of ICU Delirium
Condition(s):Delirium; AgitationLast Updated:August 2, 2012Terminated
33
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Condition(s):Obesity; Weight Gain; Psychotropic Induced Weight GainLast Updated:December 28, 2018Completed
34
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
Condition(s):StrokeLast Updated:August 8, 2019Completed
35
Staccato Prochlorperazine Single Dose PK Study
Condition(s):MigraineLast Updated:January 26, 2018Completed